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Presence of paroxysmal nocturnal hemoglobinuria in patients with idiopathic portal
vein thrombosis: a single-center study
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Background/aim: Paroxysmal nocturnal hemoglobinuria (PNH) is a very rare clonal hematopoietic stem cell disease characterized by
chronic hemolytic anemia and thrombosis. We report data from a study of the occurrence of PNH among patients with idiopathic portal
vein thrombosis (PVT).
Materials and methods: Patients who were followed up with the diagnosis of idiopathic PVT were enrolled into this study. Those with
laboratory and/or imaging evidence of any local or systemic factor that could lead to PVT were excluded. PNH clone was examined in
all patients using established FLAER methodology.
Results: A total of 112 patients (42 males and 70 females), none of them had a markedly PNH clone, but 4 patients (3.6%) with confirmed
tests two times had small PNH clones (size between 3.02% and 4.62%). The median ages of PNH clone (-) and PNH clone (+) patients
were 42 (range; 24–59) vs 39 (range; 36–42) years, respectively. The median hemoglobin concentration, platelet count and leukocyte
count were lower in the PNH clone (+) group than the PNH clone (-) group. Anemia, thrombocytopenia, and leukopenia were detected
in all PNH clone (+) patients. In addition, the PNH clone positivity size in monocytes was higher than erythrocytes in all of 4 patients.
Conclusions: PNH should be considered during differential diagnosis among patients with idiopathic PVT. Small PNH clones can
be detected in PVT patients that we cannot clearly determine its relationship with PVT. We need furthermore studies to explore the
potential role of this finding.
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1. Introduction
Paroxysmal nocturnal hemoglobinuria (PNH) is an
acquired clonal stem cell disease characterized by
venous thrombosis and intravascular hemolysis, caused
by a somatic mutation in the phosphatidylinositol
N-acetylglucosaminyltransferase subunit A (PIGA)
gene located on chromosome X [1–3]. PNH occurs with
approximately equal incidence in men and women, and the
overall disease prevalence has been estimated at 2–5 cases
per 1,000,000. The mean age at onset of PNH is around
42 years, and the 5-year mortality rate is approximately
35% [4]. Clinically, PNH occurs in three different forms.
Classic (hemolytic), bone marrow deficiency syndrome
(hypoplastic), and a subclinical form [5]. Although the
disease typically manifests with signs of bone marrow
failure, thrombotic events, and chronic intravascular
hemolytic anemia particularly those affecting the
abdominal veins, are considered the most important
complication during its course.

Thrombotic events are most commonly seen in the
splenic, mesenteric, hepatic, renal and portal veins [6].
Additionally, PNH should be considered and screened for
in cases of recurrent miscarriages and renal insufficiency
are concomitant with unexplained abdominal pain,
fatigue, dysphagia, dyspnea, erectile dysfunction, iron
deficiency, and cytopenia accompanied by hemolysis
[7,8]. Flow cytometric demonstration of absent CD59
and CD55 expression is recommended as central to
the diagnosis of PNH. FLAER (Fluorescent aerolysin)
assay is acknowledged as the most appropriate detection
method for GPI antigens, and enables highly sensitive
measurements for the detection of PNH clone sizes as low
as 0.01% [9].
The aim of this study is to evaluate the presence of
paroxysmal nocturnal hemoglobinuria in patients who
were followed up with the diagnosis of idiopathic portal
vein thrombosis in the department of hematology at our
university.
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2. Materials and methods
2.1. Patients and study design
A total of 112 patients (70 females and 42 males) who were
being followed up due to idiopathic PVT in our clinic were
enrolled into this study. The study protocol conforms to
the ethical guidelines of the 1975 declaration of Helsinki
and it was approved by the ethics committee of faculty
of medicine (Ethics Committee Approval date/number:
03.07.2014/04). All patients provided written informed
consent for participation in the study and for publication of
study data. Study procedures and data recording/handling
methods were approved by the ethics committee of our
university. Those with laboratory and/or imaging evidence
of any systemic or local factor that could lead to PVT
(including prothrombin gene mutation, factor V Leiden
mutation, antiphospholipid syndrome, systemic lupus
erythematosus, celiac disease, hepatic cirrhosis, chronic
myeloproliferative diseases, malignancies, abdominal
trauma or previous surgery) were excluded. JAK2-V617F
and other activating mutations were studied to exclude
chronic myeloproliferative diseases.
2.2. PNH clone detection by flow cytometry for diagnosis
No specific threshold value was defined for CD55 and CD59
expression levels in PNH. It is necessary for diagnosis to
show at least 2 different GPI protein deficiencies in at least
two different cell lines from neutrophils, monocytes or
erythrocytes by flow cytometry. However, clone size ≥1%
is sufficient for diagnosis and these should be monitored
for PNH symptoms. Diagnostic analyses were performed
on 2 mL EDTA-blood samples. PNH clone was examined
in all patients in the flow cytometry laboratory of the
department of hematology at university hospital using
established FLAER methodology. This method is based on
the specific binding of FLAER to GPI anchors.
2.2.1. Flow cytometry
Granulocytes: Quartet marker combinations can be used
to detect PNH clones in granulocytes [10]. In this study
we used FLAER, CD24, CD15, and CD45 Monoclonal
antibodies against CD24, CD45 (5 μL) and CD15 (5 μL),
and 5 µL of FLAER were mixed with 50 µL aliquots of
EDTA blood, followed by incubation at room temperature
for 15 minutes. Cellular lysis was induced by addition of
450 μL of a 1:9 dilution of BD-FACS lysing solution. Flow
cytometry was conducted on a BD FACS Catto II machine,
where 50.000 cells were read on the CD24 versus FLAER
graphic in the FSC-SCC dot blot.
Monocytes: Quartet stain combinations can also be
used for PNH clone detection in monocytes (10). We used
FLAER, CD14, CD64, and CD45. Staining was conducted
by mixing 5 μL of anti-CD14, 5 μL of anti-CD45, and 5 μL
of anti-CD64 monoclonal antibodies with 5 μL of FLAER
in 50 µL aliquots of EDTA blood, followed by 15 min

incubation at room temperature. Lysis was conducted as
for granulocyte preparations, followed by flow cytometry
analysis of 5000 cells in the CD64 positive monocyte field.
In all patients, complete blood count and
biochemical parameters were measured. Complete
blood count was done by the cyanmethemoglobin
method in COULTER® LH 750 hematology analyzer
using commercial kits. Biochemical parameters lactate
dehydrogenase (LDH), aspartate transaminase (AST),
alanine transaminase (ALT), bilirubins and albumin) were
measured by the spectrophotometric methods in Abbot
Diagnostic Architect Ci 16200 using commercial kits. The
ferritine was measured by the chemiluminescence method
in BİO DPC Immulite 2000 analyser using commercial kits.
Portal vein thrombosis was shown by using abdominal
ultrasound with doppler imaging and abdominal CT or
MRI.
2.3. Statistical analysis
Statistical analysis of the data was performed using the
IBM SPSS 22 statistical package program. Descriptive
statistics for studied variables (characteristics) were
presented as median, minimum and maximum values,
and for categorical variables the frequency is expressed
as a percentage [n (%)]. For determining the relationship
between groups and categorical variables, the chi-square
test was used. In order to compare PNH positive and
negative patients for demographic, clinical and laboratory
characteristics, the Man-Whitney U test was performed.
The level of significance was set at P < 0.05.
3. Results
A total of 112 patients with idiopathic PVT were enrolled
into the present study. Forty two cases (37.5%) were male
and 70 cases (62.5%) were female. PNH clone positivity
was identified in 4 patients (3.6%), the remaining 108
patients were PNH clone negative. The median ages of
PNH clone (-) and PNH clone (+) patients were 42 (range;
24–59) vs 39 (range; 36–42) years, respectively.
Anemia, thrombocytopenia, and leukopenia were
detected in all of 4 (100%) PNH clone (+) patients.
However, anemia for 58 (53.7%) cases, thrombocytopenia
for 20 (18.5%) cases, and leukopenia for 28 (25.9%) cases
were detected in the PNH clone (-) group. There was
a difference between the PNH clone (-) and PNH clone
(+) groups in terms of the median serum LDH level (164
U/L vs 312 U/L), total bilirubin level (12 mg/dL vs 2.6
mg/dL) and ferritin level (61.3 ng/dL vs 19.3 ng/dL). The
demographic, clinical, and laboratory characteristics of
these included patients are described in Table 1.
There was 1 male and 3 female patients in the PNH
clone (+) group. The clone size was between 3.02% and
4.62% in the monocytes series in these patients. PNH clone
positivity size in monocytes was higher than erythrocytes
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Table 1. Comparison for demographic, clinical, and laboratory characteristics of PNH clone positive
and PNH clone negative group.
Parameters

PNH clone (-) group

PNH clone (+) group

Number of patients, n (%)

108 (96.4)

4 (3.6)

Male

41 (37.9)

1 (25)

Female

67 (62.1)

3 (75)

Median

42

39

Range

24–59

36–42

58 (53.7)

4 (100)

Median

10.5

10.3

Range

10.1–15.2

9.1–10.9

28 (25.9)

4 (100)

Median

4.8

3.26

Range

2.1–9.8

1.8–3.3

20 (18.5)

4 (100)

Median

104.8

98.1

Range

32.2–428

87.9–105.6

Median

164

312

Range

108–238

284–350

Median

1.2

2.6

Range

0.7–1.6

1.9–2.8

Median

61.3

19.3

Range

48.8–80.8

18.1–20.8

Sex, n (%)

Age, year

Anemia, n (%)
Hemoglobin level (g/dL)

Leukopenia, n (%)
Leukocyte count (×109/L)

Thrombocytopenia, n (%)
Platelet count (×10 /L)
9

Lactate dehydrogenase (U/L)

Total bilirubin (mg/dL)

Ferritin (ng/dL)

in all of 4 patients. Characteristics of PNH clone (+) cases
showed in Table 2.
4. Discussion
PVT may arise due to a number of factors. In the majority of
cases, local factors play a role in its etiology and, frequently,
more than one coexist. In the general population, the
lifetime risk of developing PVT is approximately 1% [11].
PNH is very rare among patients with intra-abdominal
vein thrombosis related to any cause [12,13]. In the
course of PNH, venous thrombosis is the major event
that affects the life. Abdominal venous thrombosis may
occur as hepatic, mesenteric, splenic, renal and portal
vein thrombosis [14]. Hepatic vein thrombosis is more
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commonly seen compared to PVT due to increased blood
flow and decreased blood pressure and pH coexistent
hepatic vein involvement is therefore common in patients
with PVT [15,16].
During eight years of follow up in 220 patients with
PNH in a previous study, pancytopenia, thrombosis
and myelodysplastic syndrome were observed in 15%,
28% and 5% of patients, respectively [17]. In particular,
venous thrombosis during the course of the PNH is
considered a major and potentially life-limiting event
as it is associated with 40%–67% of deaths among
patients affected by PNH [2,13]. Although the cause of
thrombosis in PNH has not been fully elucidated, it is
thought that activated complement predisposes patients

DEMiR et al. / Turk J Med Sci
Table 2. Characteristics of PNH positive cases.
Parameters

Case 1

Case 2

Case 3

Case 4

Age

36

39

42

40

Sex

Male

Female

Female

Female

Vein thrombosis area

PV

PV + SV

PV

PV

Hemoglobin (g/dL)

9.1

10.3

9.8

10.9

Leukocyte (×109/L)

1.80

2.67

3.30

3.26

Platelets (×10 /L)

92.4

87.9

98.1

105.6

Lactate dehydrogenase (U/L)

292

284

312

350

Total bilirubin (mg/dL)

2.1

2.8

2.6

1.9

Indirect bilirubin (mg/dL)

1.2

1.7

1.8

1.3

Monocytes clone size (%)

3.32

3.02

4.62

3.86

Erythrocyte clone size type II (%)

0.18

0.89

0.06

1.46

Erythrocyte clone size type III (%)

1.12

2.18

0.12

0.21

9

FLAER

PV: Portal vein; SV: Splenic vein.

to thrombosis by indirectly promoting platelet aggregation
and hypercoagulability. In our PNH positive cases there
were no local or systemic risk factors typically associated
with PVT, and there was no history of thrombosis in other
intraabdominal veins (including the hepatic vein) or arterial
systems.
Intermittent
hemoglobinuria,
coombs-negative
hemolytic anemia, LDH elevation, thrombosis,
granulocytopenia and/or thrombocytopenia are often
observed during the course of PNH [18]. In our PNH clone
(-) group, 58 (51.8%) patients had anemia, 20 (18%) had
thrombocytopenia and 28 (25%) had leukopenia. A total of
61 (54.5%) patients had splenomegaly, including all patients
with leukopenia and thrombocytopenia and 13 of those
with anemia. There was no evidence of hemolytic anemia
in patients with splenomegaly. Therefore, it was considered
that cytopenia is associated with hypersplenism in these
patients.
The PNH clone (+) patients had pancytopenia. Vitamin
B12 and folic acid levels were normal in these patients with
pancytopenia. Coombs tests were negative and indirect
bilirubin levels were high in the patients. Retrospective
analysis of their medical history identified a fluctuating
course of LDH elevations. The coexistence of these findings
suggested the presence of a hemolytic process. Ferritin levels
of these patients were also found to be decreased, suggesting
borderline iron deficiency. Spleens of these patients
were also large, suggesting that eventual hypersplenism
contributed to the development of cytopenia.
Data suggest that the risk of thrombosis in PNH
is associated with PNH clone size [19]. According to

the results of two large studies, in patients who have
thrombosis, PNH clone frequency (inside granulocytes)
was measured higher than 50% and 61% [19,20].
However, lower clone sizes have been detected in some
reported cases of thrombosis in patients affected by PNH.
Ageno et al. evaluated 202 patients with splanchnic vein
thrombosis, reporting clone sizes of 0.01% and 0.16%
in two patients (incidence 1%), one with PVT without
any risk factors and the other with superior mesenteric
vein thrombosis due to inflammatory intestinal disease,
respectively [21]. Ahluwalia et al. reported PNH clones
in two patients with PVT in a cohort of 142 patients
with intraabdominal venous thrombosis (incidence
1.4%), and Qi et al. detected PNH clones in one patient
out of 100 with PVT (incidence 1.0%) [22,23]. We
excluded patients with diseases that could lead to PVT
in this study, and detected a FLAER/CD24-negative
PNH clones (size 3.02%–4.62%) in 4/112 patients with
clinical PVT, indicating an incidence of 3.6% in this
cohort. The relatively higher incidence of PNH in our
cohort compared with the three other listed studies
could be due to the fact that patients with known PVT
related to other diseases were not included. In our study,
the number of PNH clone (+) patients and the detected
clone level were small. Therefore, it is not possible to say
that the cause of PVT was these patients with PNH clone
positivity.
It is appropriate to conduct treatment-free monitoring
for asymptomatic or mildly affected patients with PNH
clone sizes below 10% [24]. In our study, in the current
identified cases with a PNH clone below 10% in size, we
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decided that anticoagulant therapy with periodic PNH
clone monitoring was the most appropriate approach.
In conclusion, we report a study to assess the presence
of PNH clones in patients with idiopathic portal vein
thrombosis. Small PNH clones can be detected in PVT
patients that not clearly determine its relationship with
PVT. Because of the small number of patients in our
study, it is difficult to determine both this relationship and
frequency of PNH in idiopathic PVT patients. Therefore,
we believe that future studies should explore the potential
role of small PNH clones in this situation of patients with
idiopathic PVT.
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